World CNS Therapeutics Market

• Publication date: May 2008
• Report size: 527 pages

This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin Americ...

This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 131 companies including many key and niche players worldwide such as Abbott Laboratories, Akzo Nobel NV, Organon N.V., Alkermes, Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, CeNeS Pharmaceuticals PLC, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Elan Corporation PLC, Eli Lilly and Co, Fabre-Kramer Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceutica NV, Janssen-Cilag, Merck & Co, Inc., Neurocrine Biosciences, Inc., Novartis AG, Sandoz International GmbH, Organon N.V., Ortho-McNeil Neurologics, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi-Aventis, Schwarz Pharma AG, Sepracor, Inc., Shire PLC, Solvay Pharmaceuticals S.A., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd, UCB S.A., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Global Therapy Industry

CNS THERAPEUTICS MCP-1835
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
CNS Disorders I-3
A. Anti-Alzheimer's Drugs I-3
B. Anti-Parkinson's Drugs I-4
C. Anti-Epilepsy Drugs I-4
D. Pain Management Drugs I-4
E. Anti-Psychotics Drugs I-5
(i) Bipolar disorder I-5
(ii) Schizophrenia I-5
F. Anti-Depressants Drugs I-5
G. Others I-6
(i) Attention Deficit Hyperactivity Disorder I-6
(ii) Multiple Sclerosis I-6
(iii) Insomnia I-6
(iv) Restless Legs Syndrome I-7
(v) Anxiety I-7


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Factors Influencing Demand II-1
The ‘Age Factor’ II-1
Role of Diagnostic Techniques II-1
Increasing Disease Awareness II-1
Emergent Technologies II-1
Reimbursement Policies II-2
Market Trends and Issues II-2
Booming Therapeutic Opportunities for Neuro-Degenerative
Disorders II-2
Spur in CNS Drug Delivery Technologies II-2
Migraine Market Offers Growth Opportunities to Prophylaxis
Products II-3
Demand for Therapeutic Peptides Spurred by Dearth of
Effective Therapies II-3
Anti-Depressants II-3
Major Trends in the Depression Market II-4
SSRIs are the Preferred Choice Despite Side Effects II-4
Table 1: US Anti-Depressants Market (2004-2006): Sales of
Leading Drug Brands - Zoloft, Effexor ER, Lexapro,
Wellbutrin, Paxil, Celexa and Prozac (In US$M) (includes
corresponding Graph/Chart) II-5

Table 2: Leading Brands in European Anti-Depressants Market
(2005): Percentage Breakdown by Value Sales for Effexor,
Zoloft, Paxil, Cipralex, Wellbutrin, Citalopram, Prozac,
Remeron and Others (includes corresponding Graph/Chart) II-5
Attention Deficit Hyperactivity Disorder (ADHD) II-5
Table 3: Worldwide ADHD Market (2005): Sales of Leading
Drug Brands -Concerta, Adderall/ Adderall ER and Strattera
(includes corresponding Graph/Chart) II-6
Major Trends in the ADHD Market: II-6
Anti-Psychotics Market II-6
Restrictions on Promotion Hamper Market Prospects II-7
Table 4: Worldwide Atypical Anti-Psychotics Market (2004 &
2005): Sales of Leading Drug Brands - Zyprexa, Risperdal,
Seroquel, Abilify and Zeldox (includes corresponding
Graph/Chart) II-7

Table 5: Leading Brands in Worldwide Anti-Psychotics Market
(Bipolar Disorder) (2003-2005): Percentage Breakdown by
Value Sales for Zyprexa, Risperdal, Seroquel, Abilify and
Others (includes corresponding Graph/Chart) II-8

Table 6: Leading Brands in US Anti-Psychotics Market
(2004-2006): Percentage Breakdown by Value Sales for
Zyprexa, Risperdal, Seroquel, Depakote/ER, Abilify,
Lamictal/XR, Geodon and Others (includes corresponding
Graph/Chart) II-9

Table 7: Leading Brands in European Atypical
Anti-Psychotics Market (2004): Percentage Breakdown by
Value Sales for Zyprexa, Risperdal/ Risperdal CONSTA,
Seroquel, Solian, Risperidone, Geodon and Others (includes
corresponding Graph/Chart) II-10
Insomnia II-10
Anti-Insomnia Drugs from Corporate Giants Flood the Sleep
Market II-10
Neuropathic Pain II-10
Table 8: Leading Players in the US Pain Management Market
(2005): Percentage Breakdown by Value Sales for J&J, Endo
Pharmaceuticals, Purdue Pharma, Cephalon, King/Ligand and
Others (includes corresponding Graph/Chart) II-11
Patent Expiry of Leading CNS Drugs: 2005-2017 II-11

2. Global Market Analysis II-12
By Region II-12
By Segment II-12

3. CNS Disorders - An Introduction II-13
Definition II-13
Central Nervous System II-13
Mortality Threat of CNS Disorders II-13
Science of NMDA Receptors and its Disease Significance II-13
Major CNS Disorders: II-14
Alzheimer’s Disease II-14
Alzheimer’s Affect on Brain II-14
Causes for Alzheimer’s II-15
Who Are at Risk? II-15
Prevalence of Alzheimer’s Disease II-16
Table 9: Incidence of Alzheimer’s Disorder in Major US
States: 2000-2025 (includes corresponding Graph/Chart) II-16

Table 10: Leading Brands in the US Anti-Alzheimer’s Market
(2004-2005): Percentage Breakdown by Value Sales for
Aricept, Namenda, Razadyne/ Razadyne ER and Exelon
(includes corresponding Graph/Chart) II-17
Diagnosis of Alzheimer’s II-17
Treatment for Alzheimer’s II-17
Parkinson’s Disease II-18
Table 11: Leading Brands in Worldwide Anti-Parkinson’s
Disease Market (2005): Percentage Breakdown by Value Sales
for Mirapex, Requip, Cabaser, Madopar, Stalevo and Others
(includes corresponding Graph/Chart) II-18
Prevalence of Parkinson’s II-19
Symptom of Parkinson’s II-19
Causes of Parkinson’s II-19
Parkinson’s Diagnosis II-20
Therapies for Parkinson’s II-20
Surgery: The Last Option II-20
Epilepsy II-21
Table 12: Worldwide Epilepsy Market (2004-2005): Sales of
Leading Drug Brands - Topamax, Lamictal, Depakote, Neurontin
and Trileptal (In US$ Million) (includes corresponding
Graph/Chart) II-21
Therapies for Epilepsy II-21
Pain Management II-22
Debilitating Effects of Pain II-23
Types of Pain II-23
Acute Pain II-23
Chronic Pain II-23
Migraine II-23
Neuropathic Pain II-23
Nociceptive Pain II-24
Pain Management Therapies II-24
Bipolar Disorder II-24
Symptoms of Bipolar Disorder II-24
Therapies for Bipolar Disorder II-25
Schizophrenia II-25
Symptoms of Schizophrenia II-25
Therapies for Schizophrenia II-25
Depression II-25
Prevalence of Depression II-26
Causes of Depression II-26
Types of Depressive Disorders II-26
Available Treatment II-26
Tricyclic Antidepressants II-27
Monoamine Oxidase Inhibitors II-27
Lithium Salts II-27
Working of Antidepressants II-27
Ranking of Antidepressants in Terms of Efficacy II-27
Types of Antidepressants II-28
NMDA Receptor Antagonists II-28
NMDA Receptor (NMDAR) II-28
NMDA Receptor Agonists II-28
Acetylcholinesterase Inhibitors II-28
Selective Serotonin Reuptake Inhibitors (SSRIs) II-29
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) II-29
Others Common CNS Disorders II-30
Attention Deficit Hyperactivity Disorder II-30
Consequences of ADHD II-30
What Leads to ADHD? II-31
Treating ADHD II-31
Multiple Sclerosis (MS) II-31
Types of Multiple Sclerosis II-32
Prevalence of MS II-32
Causes of MS II-32
Myths Surrounding Multiple Sclerosis II-32
Symptoms of MS II-33
Diagnosis of MS II-33
Therapies for MS II-33
Insomnia II-33
Prevalence of Insomnia II-33
Therapies for Insomnia II-34
Restless Legs Syndrome II-34
Anxiety II-34

4. Overview of Select CNS Drugs II-35
Anti-Alzheimer’s Drugs II-35
Aricept II-35
Exelon II-35
Reminyl II-35
Ebixa II-35
Namenda II-35
Anti-Parkinson’s Drugs II-36
Levodopa II-36
Dopamine Agonists II-36
Mirapex II-36
Requip II-36
Anti-Epilepsy Drugs II-36
Carbamazepine II-36
Phenytoin II-36
Lamictal II-37
Depakote II-37
Neurotonin II-37
Pain Management II-37
Duragesic II-37
Metabotropic Glutamate Receptors (mGluRs) II-37
Anti-Psychotics II-38
Zyprexa II-38
Seroquel II-38
Abilify II-38
Clozaril II-38
Antidepressants Drugs II-38
Zoloft (Sertraline) II-38
Prozac (Fluoxetine) II-39
Effexor (Venlafaxine) II-39
Paxil II-39
Wellbutrin (Bupropion) II-39
Attention Deficit Hyperactivity Disorder (ADHD) II-39
Concerta II-39
Strattera II-40
Adderall II-40
Insomnia II-40
Estorra II-40
Lunesta II-40

5. Research & Development II-41
AstraZeneca, NPS Develop mGluRs for CNS Disorders II-41
High Efavirenz Plasma Levels in HIV Patients Could Result in
CNS Toxicity II-41
Adenoviral Gene Therapy May Damage CNS II-41
Role of B Cells in Damaging Nerve Fibers II-41
Oral Administration of Antibodies Restrict Attacks in MS II-42
Country of Birth/Dwelling Influences Risk of Multiple Sclerosis II-42
Levetiracetam is Effective in Epilepsy Prevention II-42
Nicotine Guards Against Parkinson’s-Like Disease II-42
Parkinson’s Drugs May Influence Addictions II-43
Dopamine Induces Sleep and Brain Activity II-43
Researchers Link Obesity to Dementia II-43
High Folate Consumption Mitigates Risks to Alzheimer’s Disease II-43
Consistent Depression Treatment Likely to Prevent Relapse II-43
Animal Research Model Highlights Difficulties of Depression
Syndrome II-43
Hypnion Announces Encouraging Results for HY10275 II-44
Antihistamine Effective In Mitigating Alzheimer’s Disorder II-44
Novartis’ Fingolimod Alleviate MS Activity II-44
Lundbeck Initiates Trials of its Novel Anti-Psychotic Drug II-44
Cara Develops CR665 for Pain Management II-44
Gepirone ER of Fabre-Kramer Effective in Depression II-44
Biogen Idec Discovers Molecule for Treatment of CNS Disorders II-45
Teva Claims Copaxone as the Ultimate in Treating MS II-45
Biogen Idec and Elan Corp. Conclude Safety Evaluation of Tysabri® II-45
Cognetix Files Provisional Patent for Screening Methods of
CGX-1160 II-45
NeuroSearch’s NS2330 Fail to Meet Efficacy Standards in Trials II-45
Medtronic Undertakes Trials to Study Treatment Resistant
Depression II-45
National MS Society to Initiate Efforts to Identify MS
Influencing Genetics II-45
Academic Data Supports COMT Inhibitors Performance in Parkinson’s II-46
MS Ireland Supports Return of Tysabri II-46
Cigarette Smoking Increases Risks of Multiple Sclerosis II-46
Study of Parkinson’s Incidence in Zambia, Russia and Uzbekistan II-46
Encouraging Developments in Animal Model of Parkinson’s Disease II-46

6. Product Innovations/Introductions II-47
Biogen and Elan Introduces Tysabri in Europe II-47
Medtronic Launches Activa® for Parkinson’s Disease II-47
Tysabri Obtains Canadian Approval For Multiple Sclerosis II-47
Lundbeck Unveils Serdolect® Available in Estonia II-47
OPC, Bristol-Myers Unveil Abilify® Discmelt™ II-47
OPC Introduces Anti-Psychotic Drug Abilify in Japan II-47
FDA Approves Novartis’ Exelon for Parkinson’s II-48
Ono Pharmaceutical, Novartis Develops Transdermal Patch for
Alzheimer’s II-48
Zydus Cadila Drugs Flood the French Pharmaceutical Market II-48
Schwarz Pharma Develops Anti-Parkinson’s Drug II-48
Azilect® Enters European Market II-48
Lilly Launches Therapy for Bipolar Disorder II-48

7. Recent Industry Activity II-49
P1vital Creates Global Consortium to Develop CNS Experimental
Medicine II-49
Neurobiological Tech Teams Up with Buck Institute II-49
ExonHit Therapeutics and Allergan Ink Contract to Develop CNS
Agents II-49
NeuroSearch Commences Clinical Phase I study with NSD-788 in
France II-49
Abilify® Meets CHMP Standards II-49
UCB Receives Recommendation for Approval for Neupro® II-49
Schering-Plough Acquires Organon II-50
UCB Launches Neupro® in the US II-50
GlaxoSmithKline Forms Alliance with Targacept II-50
GSK Teams-Up with Sepracor for Commercializing Lunivia® II-50
US FDA Rebut NDA for bifeprunox II-51
Medtronic and Alnylam Extend their Drug-Device Collaboration II-51
Neuren Takes Over Hamilton II-51
Roche Forms Partnership with Synosis Therapeutics to Evaluate
Five CNS Compounds II-51
NeuroSearch Starts Clinical Phase I Study with ACR343 in Sweden II-51
Lundbeck to Promote Circadin® in Europe II-51
Sepracor Inks Partnership with Eisai to Develop and Market
Lunesta® in Japan II-52
Neurologix Obtains License of Gene Therapy Component II-52
Prestwick Raises Fund to Finance CNS Projects II-52
Kyowa Inks Agreement with Britannia II-52
China Aoxing Pharmaceutical Receives Product Approvals II-53
China Aoxing Acquires Hebei Aoxing II-53
AlphaRx Partners with Israel based PharmSeed Ltd II-53
Nippon Boehringer Markets CNS Drugs on Portals II-53
FDA Approves Tysabri for treating MS II-53
CeNeS Acquires Certain IP Rights from ALZA II-53
Belgium based UCB Acquires Schwarz Pharma II-54
Axaron and LION Bioscience Establish New Company II-54
Ceregene Obtains Grant for Phase II Trial II-54
Shire Obtains Anti-Epileptic Drug License from Yissum II-54
TorreyPines and Axonyx Conclude Merger Operations II-54
VistaGen Enters Into Strategic Partnership with Cato BioVentures II-54
Organon Announces Partnership with BrainCells II-55
Alkermes Inks Licensing Agreement with Rensselaer II-55
FDA Approves SEROQUEL® Therapy for Bipolar Indication II-55
Boehringer Ingelheim, Eli Lilly Modify Agreement Terms II-55
Boston Life Sciences Signs Licensing Agreement with Children’s
Hospital II-55
CeNeS, Tripos Extend Research Collaboration II-55
CeNeS Partners Ergomed for CNS 5161 Phase II Clinical Trial II-56
CeNeS’ Short-Acting Sedative Obtains Patent II-56
Takeda and Cephalon Collaborate Over Provigil® II-56
Eli Lilly Files sNDA for Cymbalta® II-56
GlaxoSmithKline Obtains FDA Approval for Lamictal® II-56
Serono Acquires Safinamide License from Neuron II-56
Neurocrine Files NDA for Anti-Insomnia Drug Indiplon II-56
Novartis Inks Agreement with Servier, Idenix II-57
NPS Extends Alliance with AstraZeneca II-57
Pfizer’s Lyrica® Receives Approval for Neuropathic Pain II-57
Schwarz Pharma Receives FDA Approval of Neupro® II-57
Teva’s Azilect® tablets Approved in Canada II-57
Teva and Eisei Terminate Joint Marketing Alliance II-57
FDA Approves Teva’s Azilect® for Parkinson’s Disorder II-58
UCB’s Keppra® Obtains FDA Approval to Treat Epilepsy II-58
Wyeth, Solvay Pharmaceuticals Files NDA for Schizophrenia Drug II-58
D-Pharm Licenses DP-b99 Drug to Yungjin II-58
Eli Lilly, Suven Collaborate Over CNS Therapies II-58
IVAX to Develop Oral Therapy for Multiple Sclerosis II-58
Thomson Takes Over Cipher’s Business Unit II-58
CLL Pharma Acquires Synt: em SA II-59
Ranbaxy Acquires Advent’s Subsidiary II-59
Shire Receives Approval of Daytrana for Treating ADHD Disorder II-59
Shire Inks Marketing Agreement with New River II-59
Acadia and Sepracor in a Collaborative R&D Deal II-59
Ablynx Partners with National Research Council of Canada II-59
Bristol Myers and Albany Sign Licensing Agreement II-60
Andara Secures Licenses to Purdue’s Treatment Alternatives II-60
Otsuka Ties Up with Galenea to Develop CNS drugs II-60
Novartis Inks Distribution Agreement with Alfresa Pharma II-60
Dainippon Commences Operations of New Facility II-60
Ranbaxy Purchases Generic Product Line of Efarmes II-60
Novasite Takes Over PsyCheNomicS II-61
Organon Returns Gepirone ER Rights to Fabre-Kramer II-61
Teva Expands Operations in India II-61
Neurologix Acquires License to Alzheimer’s Treating Gene II-61
Meda Takes Over Viatris II-61
Evotec Acquires Majority Stake in Evotec Neurosciences II-61
IVAX Merges with Teva Pharmaceutical II-62
Wyeth Files NDA for Anti-Depressant Drug DVS-233 II-62
Schwarz Pharma Acquires Rights of Rotigotine II-62
Shire Submits NDA for Two ADHD Drugs II-62
Takeda and Paradigm Collaborate to Develop CNS Therapies II-62
Sanofi’s Ambien CR™ to Induce and Maintain Sleep in the US II-62
NeuroSearch Initiates Phase I Clinical Study of ABT- 894 II-62
NeuroSearch Receives Euro 10 Million as Milestone Payments for
NS2359 II-62
FDA Approves Depakote® ER for Bipolar Disorder Treatment II-63
Alkermes Receives Approval for Risperdal Consta® in Italy II-63
AstraZeneca Signs Research Collaboration Deal with Targacept II-63
Cymbalta® / Xeristar® Treatment Approved for Depression in Europe II-63
FDA Grants SPA Status to Boston Life’s Altropane® II-63
Sumitomo Merges with Dainippon II-63
Cipralex® Therapy Extended to GAD in Europe II-63
Johnson & Johnson Submits Paliperidone ER for NDA II-64
Spectrum Acquires License of CNS Cancer Therapeutic Drug II-64
Multiple Sclerosis Drug Tysabri Pulled Off Market II-64
Roche Partners with GE Healthcare II-64
New River to Develop Pain Management Therapies II-64
Elekta Takes Over IMPAC Medical Systems II-64
Eli Lilly Acquires Merck’s Product Compound for Insomnia II-64
Prestwick Raises Funds to Develop CNS Therapies II-65
Aspect Medical Acquires Exclusive Rights to Cordance Technology II-65
Bristol-Myers Pulls Out Serzone from the US Market II-65
Paladin Inks Agreement with Ovation II-65
Acorda Raises Funds For Therapy Development II-65
Wyeth Sells Indiplon Ownership Rights to Neurocrine II-65
Micrologix Takes Over Mitokor II-66
Sanofi Merges with Aventis to Form a New Company II-66
VistaGen Takes Over Artemis II-66
Neuro Bioscience Acquires Majority Stake in CLL Pharma II-66
Tiger Brands Acquires Pfizer’s Subsidiary II-66
Pfizer Acquires Asenapine License from Organon II-66

8. Focus on Select Global Players II-67
Abbott Laboratories (USA) II-67
Alkermes, Inc. (USA) II-67
AstraZeneca Plc (UK) II-67
Boehringer Ingelheim GmbH (Germany) II-67
Bristol-Myers Squibb (USA) II-68
CeNeS Pharmaceuticals Plc (UK) II-68
Cephalon, Inc. (USA) II-68
Dainippon Sumitomo Pharma Co., Ltd. (Japan) II-69
Elan Corporation Plc (Ireland) II-69
Eli Lilly and Co. (USA) II-69
Fabre-Kramer Pharmaceuticals, Inc. (USA) II-70
F. Hoffmann-La Roche Ltd. (Switzerland) II-70
Forest Laboratories, Inc. (USA) II-70
GlaxoSmithKline (UK) II-70
H. Lundbeck A/S (Denmark) II-71
Johnson & Johnson (USA) II-71
Janssen Pharmaceutica N.V. (Belgium) II-71
Janssen-Cilag (Switzerland) II-71
Merck & Co, Inc. (USA) II-71
Neurocrine Biosciences, Inc. (USA) II-72
Novartis AG (Switzerland) II-72
Sandoz International GmbH (Germany) II-72
Organon N.V. (The Netherlands) II-73
Ortho-McNeil Neurologics, Inc. (USA) II-73
Otsuka Pharmaceutical Co., Ltd. (Japan) II-73
Pfizer, Inc. (USA) II-73
Sanofi-Aventis (France) II-74
Schwarz Pharma AG (Germany) II-74
Sepracor, Inc. (USA) II-74
Shire Plc (UK) II-74
Solvay Pharmaceuticals S.A. (France) II-75
Takeda Pharmaceutical Co., Ltd. (Japan) II-75
Teva Pharmaceutical Industries Ltd. (Israel) II-75
UCB S.A. (Belgium) II-75
Wyeth (USA) II-76

9. Global Market Perspective II-77
Table 13: World Recent Past, Current & Future Analysis for CNS
Therapeutics by Geographic Region - USA, Canada, Europe,
Asia-Pacific (including Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-77

Table 14: World Long-term Projections for CNS Therapeutics by
Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-78

Table 15: World 10-Year Perspective for CNS Therapeutics by
Geographic Region - Percentage Breakdown of Dollar Sales for
USA, Canada, Europe, Asia-Pacific (including Japan), Latin
America and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-79

Table 16: World Recent Past, Current & Future Analysis for
Anti-Alzheimer's Drugs by Geographic Region - USA, Canada,
Europe, Asia-Pacific (including Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-80

Table 17: World Long-term Projections for Anti-Alzheimer's
Drugs by Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-81

Table 18: World 10-Year Perspective for Anti-Alzheimer's Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for USA, Canada, Europe, Asia-Pacific (including Japan),
Latin America and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-82

Table 19: World Recent Past, Current & Future Analysis for
Anti-Parkinson's Drugs by Geographic Region - USA, Canada,
Europe, Asia-Pacific (including Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-83

Table 20: World Long-term Projections for Anti-Parkinson's
Drugs by Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-84

Table 21: World 10-Year Perspective for Anti-Parkinson's Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for USA, Canada, Europe, Asia-Pacific (including Japan), Latin
America and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-85

Table 22: World Recent Past, Current & Future Analysis for
Anti-Epilepsy Drugs by Geographic Region - USA, Canada,
Europe, Asia-Pacific (including Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-86

Table 23: World Long-term Projections for Anti-Epilepsy Drugs
by Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-87

Table 24: World 10-Year Perspective for Anti-Epilepsy Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for USA, Canada, Europe, Asia-Pacific (including Japan), Latin
America and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-88

Table 25: World Recent Past, Current & Future Analysis for
Pain Management Drugs by Geographic Region - USA, Canada,
Europe, Asia-Pacific (including Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-89

Table 26: World Long-term Projections for Pain Management
Drugs by Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-90

Table 27: World 10-Year Perspective for Pain Management Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for USA, Canada, Europe, Asia-Pacific (including Japan),
Latin America and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-91

Table 28: World Recent Past, Current & Future Analysis for
Anti-Psychotics Drugs by Geographic Region - USA, Canada,
Europe, Asia-Pacific (including Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-92

Table 29: World Long-term Projections for Anti-Psychotics
Drugs by Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-93

Table 30: World 10-Year Perspective for Anti-Psychotics Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for USA, Canada, Europe, Asia-Pacific (including Japan), Latin
America and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-94

Table 31: World Recent Past, Current & Future Analysis for
Anti-Depressants Drugs by Geographic Region - USA, Canada,
Europe, Asia-Pacific (including Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-95

Table 32: World Long-term Projections for Anti-Depressants
Drugs by Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-96

Table 33: World 10-Year Perspective for Anti-Depressants Drugs
by Geographic Region - Percentage Breakdown of Dollar Sales
for USA, Canada, Europe, Asia-Pacific (including Japan),
Latin America and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-97

Table 34: World Recent Past, Current & Future Analysis for
Other Drugs by Geographic Region - USA, Canada, Europe,
Asia-Pacific (including Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-98

Table 35: World Long-term Projections for Other Drugs by
Geographic Region - USA, Canada, Europe, Asia-Pacific
(including Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-99

Table 36: World 10-Year Perspective for Other Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
USA, Canada, Europe, Asia-Pacific (including Japan), Latin
America and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-100


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current & Future Analysis III-1
Cost Implications of CNS Disorders III-1
Alzheimer's Market III-1
Table 37: Incidence of Alzheimer's Disorder in Major US
States: 2000-2025 (includes corresponding Graph/Chart) III-2
Anti-Alzheimer's Drugs Approved for Use in the Past III-2
Table 38: Leading Brands in the US Anti-Alzheimer's Market
(2004 & 2005): Percentage Breakdown by Value Sales for
Aricept, Namenda, Razadyne / Razadyne ER and Exelon
(includes corresponding Graph/Chart) III-3
Cost of Care to AD Patient III-3
Clinical Pipeline III-3
Anti-Psychotics III-3
Growth Dampeners III-4
Clinical Pipeline III-4
Table 39: Leading Brands in US Anti-Psychotics Market
(2004-2006): Percentage Breakdown by Value Sales for
Zyprexa, Risperdal, Seroquel, Depakote/ER, Abilify,
Lamictal/XR, Geodon and Others (includes corresponding
Graph/Chart) III-5

Table 40: Leading Brands in US Atypical Anti-Psychotics
Market (2004, 2006 & 2008): Percentage Breakdown by Value
Sales for Zyprexa, Risperdal/ Risperdal CONSTA, Seroquel,
Abilify, Geodon and Others (includes corresponding
Graph/Chart) III-5
Antidepressants III-6
Antidepressants to Feature Black-Box Warnings III-6
Antidepressant Consumption Falls Among Children and
Adolescents III-6
Table 41: US Anti-Depressants Market (2004-2006): Sales of
Leading Drug Brands - Zoloft, Effexor ER, Lexapro,
Wellbutrin, Paxil, Celexa and Prozac (includes
corresponding Graph/Chart) III-6
Multiple Sclerosis III-7
Table 42: Leading Anti-Multiple Sclerosis Drugs in the US
(2004): Percentage Breakdown of Value Sales for Avonex,
Copaxone, Rebif and Betaseron (includes corresponding
Graph/Chart) III-7
Insomnia Market III-7
Rising Consumption of ADHD Drugs Combat Safety Concerns III-7
Table 43: US ADHD Market (2005): Percentage Breakdown of
Sales by Leading Brands - Concerta, Strattera, Ritalin,
Metadate, Focalin XR and Others (includes corresponding
Graph/Chart) III-8
Unmet Medical Needs in Neuropathic Pain Offer Growth Prospects III-8
Table 44: Leading Players in the US Pain Management Market
(2005-2007): Percentage Breakdown by Value Sales for J&J,
ENDO, Purdue, Cephalon, King/Ligand and Others (includes
corresponding Graph/Chart) III-8
CNS Tuberculosis Raises its Ugly Head III-9
Product Launches/Developments III-9
Strategic Corporate Developments III-10
Key Players III-20
B.Market Analytics III-26
Table 45: US Recent Past, Current & Future Analysis for CNS
Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-26

Table 46: US Long-term Projections for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-27

Table 47: US 10-Year Perspective for CNS Therapeutics by
Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-28

2. Canada III-29
A.Market Analysis III-29
Current & Future Analysis III-29
Facts & Figures III-29
Strategic Corporate Developments III-29
Neurochem, Inc. - A Major Player III-30
B.Market Analytics III-31
Table 48: Canadian Recent Past, Current & Future Analysis
for CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-31

Table 49: Canadian Long-term Projections for CNS
Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-32

Table 50: Canadian 10-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-33

3. Europe III-34
A.Market Analysis III-34
Current & Future Analysis III-34
By Region III-34
By Product Segment III-34
Anti-Psychotics Market III-34
Table 51: European Anti-Psychotics Market (2002-2006):
Percentage Breakdown of Revenues by Product Class -
Atypical Anti-Psychotics Drugs and Traditional
Anti-Psychotics Drugs (includes corresponding Graph/Chart) III-34

Table 52: Leading Brands in European Atypical
Anti-Psychotics Market (2004): Percentage Breakdown by
Value Sales for Zyprexa, Risperdal/ Risperdal CONSTA,
Seroquel, Solian, Risperidone, Geodon and Others (includes
corresponding Graph/Chart) III-35
European CNS Market Offers Untapped Opportunities III-35
Competitive Scenario of CNS Drug Market III-35
Challenges Faced by the Antidepressants Market III-35
Table 53: Leading Brands in European Anti-Depressants
Market (2005): Percentage Breakdown by Value Sales for
Effexor, Zoloft, Paxil, Cipralex, Wellbutrin, Citalopram,
Prozac, Remeron and Others (includes corresponding
Graph/Chart) III-36

Table 54: European Anti-Depressants Market (2004-2006):
Percentage Breakdown of Revenues by Segment - SSRI, SNRI
and Others (includes corresponding Graph/Chart) III-36
Product Launches/Developments III-36
Strategic Corporate Developments III-37
Key Players III-42
B.Market Analytics III-47
Table 55: European Recent Past, Current & Future Analysis
for CNS Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-47

Table 56: European Long-term Projections for CNS
Therapeutics by Geographic Region - France, Germany, Italy,
UK, Spain and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-48

Table 57: European Recent Past, Current & Future Analysis
for CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-49

Table 58: European Long-term Projections for CNS
Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-50

Table 59: European 10-Year Perspective for CNS Therapeutics
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain and Rest of Europe
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-51

Table 60: European 10-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-52

3a. France III-53
A.Market Analysis III-53
Current & Future Analysis III-53
Healthcare System in France III-53
B.Market Analytics III-54
Table 61: French Recent Past, Current & Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-54

Table 62: French Long-term Projections for CNS Therapeutics
by Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-55

Table 63: French 10-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-56

3b. Germany III-57
A.Market Analysis III-57
Current & Future Analysis III-57
Healthcare System in Germany III-57
Reimbursement Policy III-57
B.Market Analytics III-58
Table 64: German Recent Past, Current & Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-58

Table 65: German Long-term Projections for CNS Therapeutics
by Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-59

Table 66: German 10-Year Perspective for CNS Therapeutics by
Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-60

3c. Italy III-61
A.Market Analysis III-61
Current & Future Analysis III-61
Healthcare System in Italy III-61
Market Snapshots III-61
B.Market Analytics III-62
Table 67: Italian Recent Past, Current & Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-62

Table 68: Italian Long-term Projections for CNS Therapeutics
by Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-63

Table 69: Italian 10-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-64

3d. The United Kingdom III-65
A.Market Analysis III-65
Current & Future Analysis III-65
Healthcare System in the UK III-65
NICE Recommendations on CNS Therapeutics III-65
B.Market Analytics III-66
Table 70: UK Recent Past, Current & Future Analysis for CNS
Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-66

Table 71: UK Long-term Projections for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-67

Table 72: UK 10-Year Perspective for CNS Therapeutics by
Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-68

3e. Spain III-69
A.Market Analysis III-69
Current & Future Analysis III-69
Healthcare System in Spain III-69
B.Market Analytics III-70
Table 73: Spanish Recent Past, Current & Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-70

Table 74: Spanish Long-term Projections for CNS Therapeutics
by Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) III-71

Table 75: Spanish 10-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-72

3f. Rest of Europe III-73
A.Market Analysis III-73
Current & Future Analysis III-73
Overview of Select Markets III-73
Belgium III-73
Finland